Loading cancer entity…
Loading cancer entity…
Clinical trials
4,033 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (699)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02174445 | An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years(DECLINE) | terminated | Phase 3 | 14 | Prof. Dr. Nikolas von BubnoffOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT04175587 | Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL(RIF) | unknown | Phase 3 | 109 | Peking University People's HospitalOTHER |
| 0 |
| Nov 29, 2019 |
| clinicaltrials |
| NCT00568633 | Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML | terminated | Phase 3 | 58 | Stanford UniversityOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT01305200 | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant | completed | Phase 3 | 226 | Children's Oncology GroupNETWORK | 3 | Sep 17, 2019 | clinicaltrials |
| NCT04087967 | Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients | unknown | Phase 3 | 162 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT00260832 | Trial of Decitabine in Patients With Acute Myeloid Leukemia | completed | Phase 3 | 485 | Eisai Inc.INDUSTRY | 15 | Sep 11, 2019 | clinicaltrials |
| NCT04083911 | Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60 | unknown | Phase 3 | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT02474290 | Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML | completed | Phase 2 / Phase 3 | 202 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT03547154 | Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026) | terminated | Phase 2 / Phase 3 | 344 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 12, 2019 | clinicaltrials |
| NCT02292446 | Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. | completed | Phase 3 | 161 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 18, 2019 | clinicaltrials |
| NCT01178281 | Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence(RESUME) | completed | Phase 3 | 267 | CelgeneINDUSTRY | 16 | Jul 17, 2019 | clinicaltrials |
| NCT01295710 | Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) | completed | Phase 3 | 260 | Neovii BiotechINDUSTRY | 2 | Apr 9, 2019 | clinicaltrials |
| NCT01243944 | Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) | completed | Phase 3 | 222 | Incyte CorporationINDUSTRY | 18 | Mar 6, 2019 | clinicaltrials |
| NCT00574873 | Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML | completed | Phase 3 | 502 | PfizerINDUSTRY | 29 | Jan 8, 2019 | clinicaltrials |
| NCT01802333 | Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 3 | 754 | National Cancer Institute (NCI)NIH | 2 | Dec 19, 2018 | clinicaltrials |
| NCT02785900 | Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia(CASCADE) | terminated | Phase 3 | 240 | Seagen Inc.INDUSTRY | 16 | Dec 12, 2018 | clinicaltrials |
| NCT03665480 | The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT03701217 | Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML | unknown | Phase 2 / Phase 3 | 220 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT03655145 | HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation(MacHaploMud) | unknown | Phase 3 | 344 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Aug 31, 2018 | clinicaltrials |
| NCT01191801 | Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML(VALOR) | completed | Phase 3 | 711 | Sunesis PharmaceuticalsINDUSTRY | 15 | Aug 22, 2018 | clinicaltrials |
| NCT03642236 | Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT01588951 | Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior | terminated | Phase 2 / Phase 3 | 10 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT01535391 | Nilotinib in PH+, BCR-, ABL+ CML Patients(CML0811) | completed | Phase 3 | 109 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Aug 6, 2018 | clinicaltrials |
| NCT01237808 | Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation | completed | Phase 3 | 144 | University of UlmOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT00656448 | A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS | completed | Phase 3 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT03515018 | Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients(HU) | unknown | Phase 3 | 60 | First Affiliated Hospital of Harbin Medical UniversityOTHER | 1 | May 22, 2018 | clinicaltrials |
| NCT01755325 | Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+ | suspended | Phase 3 | 680 | Junmin LiOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT01460693 | Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia(SPIRIT2) | completed | Phase 3 | 814 | Newcastle UniversityOTHER | 1 | Apr 24, 2018 | clinicaltrials |
| NCT00952289 | COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial | completed | Phase 3 | 309 | Incyte CorporationINDUSTRY | 3 | Mar 12, 2018 | clinicaltrials |
| NCT02204644 | The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML | completed | Phase 3 | 400 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT01382147 | Evaluation of "Dose-dense Therapy" by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML)(AMLCG 2008) | completed | Phase 3 | 396 | Prof. Dr. Wolfgang HiddemannOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT00176839 | Stem Cell Transplantation for Hematological Malignancies | terminated | Phase 2 / Phase 3 | 11 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT01632904 | Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study | completed | Phase 3 | 110 | Incyte CorporationINDUSTRY | 7 | Nov 14, 2017 | clinicaltrials |
| NCT00151242 | Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 / Phase 3 | 920 | University of UlmOTHER | 2 | Sep 20, 2017 | clinicaltrials |
| NCT01074047 | Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML) | completed | Phase 3 | 488 | CelgeneINDUSTRY | 18 | Aug 29, 2017 | clinicaltrials |
| NCT00516503 | Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer | completed | Phase 3 | 208 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT03256071 | Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT | unknown | Phase 2 / Phase 3 | 90 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 21, 2017 | clinicaltrials |
| NCT00075478 | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | completed | Phase 3 | 87 | Fred Hutchinson Cancer CenterOTHER | 3 | May 15, 2017 | clinicaltrials |
| NCT00324324 | Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant | terminated | Phase 3 | 240 | OHSU Knight Cancer InstituteOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT00151255 | All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 3 | 500 | University of UlmOTHER | 2 | Apr 19, 2017 | clinicaltrials |
| NCT00755040 | Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder | completed | Phase 3 | 164 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT01749111 | Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis(CICLODECH) | terminated | Phase 3 | 3 | Hospital Israelita Albert EinsteinOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01126892 | A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase(ENACT) | completed | Phase 3 | 6 | Novartis PharmaceuticalsINDUSTRY | 2 | Feb 28, 2017 | clinicaltrials |
| NCT00481247 | A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia(DASISION) | completed | Phase 3 | 547 | Bristol-Myers SquibbINDUSTRY | 27 | Feb 15, 2017 | clinicaltrials |
| NCT00719563 | American Ginseng in Treating Patients With Fatigue Caused by Cancer | completed | Phase 3 | 364 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT00860639 | Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk(LAM2006IR) | completed | Phase 3 | 327 | Nantes University HospitalOTHER | 1 | Jan 27, 2017 | clinicaltrials |
| NCT01226303 | Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia | unknown | Phase 3 | 300 | Associazione Italiana Ematologia Oncologia PediatricaOTHER | 1 | Jan 26, 2017 | clinicaltrials |
| NCT02979548 | Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy | unknown | Phase 3 | 116 | Dr Atul SharmaOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT01828489 | Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years(AML2012) | unknown | Phase 3 | 300 | Vastra Gotaland RegionOTHER_GOV | 9 | Jan 10, 2017 | clinicaltrials |
| NCT02829775 | A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies | completed | Phase 2 / Phase 3 | 9 | Hoffmann-La RocheINDUSTRY | 7 | Jan 9, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Dec 2, 2019source: clinicaltrials